This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Medidata Solutions Showcases New Products And Enhancements To Clinical Cloud Platform At DIA Annual Meeting

Stocks in this article: MDSO

Medidata Solutions (NASDAQ: MDSO) will showcase new products and features that broaden its clinical cloud platform at the upcoming Drug Information Association’s (DIA) Annual Meeting, June 24-28 in Philadelphia, Pa. Addressing new industry regulations, the need for broad safety reporting and improvements to site monitoring processes, these enhancements to Medidata’s comprehensive solutions will offer drug developers new capabilities for overcoming key research challenges.

“Sponsors are under more pressure than ever to cut costs, improve efficiency and adhere to increased regulations, requiring innovation and real-time operational analytics across the clinical research chain from concept to conclusion,” said Glen de Vries, president of Medidata Solutions. “We are continuously broadening our solution set to empower sponsors to improve their research clinical systems at every point in the clinical process, including trial planning, monitoring, site payments and safety.”

From booth #3101, Medidata will be providing demos of key products and new features to enable sponsors to achieve key goals, including:

  • Driving a New Monitoring ParadigmThe company’s first solution for managing site quality and the latest addition to the Medidata Insights™ family of clinical business analytics offerings, Medidata Insights SQM™ combines advanced data visualization with seamless real-time data availability with the rest of Medidata's platform to deliver turnkey site quality management – further enabling the industry’s shift to simplified remote monitoring of site and data quality resulting from the 2011 FDA clarification on source document verification (SDV).
  • Automating Safety Processes with Electronic Adverse Event TransferTo help drug developers meet post-marketing expedited reporting obligations within the new European pharmacovigilance legislation, Medidata Rave Safety Gateway™ expanded its capabilities for sites to electronically transfer non-serious safety case data – in addition to serious safety case data – to sponsors' safety systems, eliminating paper-based manual processes, reducing query cycles between sites and sponsors’ safety groups and minimizing reconciliation between safety and clinical databases.
  • Ensuring Timely Investigator PaymentsDue to the complexity of triggering investigator payments from sponsor-set milestones, site payments are often delayed. The out-of-the box integration of Medidata CTMS™ and Medidata Rave ® electronic data capture (EDC) improves the efficiency of clinical operations, streamlining workflows in areas such as site monitoring and site payments. Now, Medidata Rave EDC data is pulled into Medidata CTMS™ monitor reports, increasing the accuracy of reporting and timeliness of payment triggers.
  • Assuring Market Value Compliance and Faster Budget AgreementsDesigned for sponsors receiving investigator-sponsored proposals from sites, Medidata Grants Manager Investigator Initiated™ offers drug developers clarity and uniformity in judging pricing and conduct of their submitted funding requests.
  • Ensuring the Right Randomization Approach to Meet Study Goals Medidata Balance™ now provides the block randomization methodology in addition to dynamic allocation randomization, extending its use to new segments of the life science industry by permitting researchers to use the approach that best suits their study goals.

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Copyright Business Wire 2010

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,085.76 +55.55 0.31%
S&P 500 2,092.26 +10.38 0.50%
NASDAQ 4,814.0280 +40.5560 0.85%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs